JP Morgan Chase
MDGL icon

JP Morgan Chase’s Madrigal Pharmaceuticals MDGL Stock Holding History

JP Morgan Chase’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-900
Closed -$278K – 7577
2024
Q4 		$278K Sell
900
-15,000
-94% -$4.22M ﹤0.01% 5333
2024
Q3 		$3.37M Hold
15,900
– – ﹤0.01% 3533
2024
Q2 		$4.45M Buy
15,900
+15,000
+1,667% +$3.57M ﹤0.01% 3117
2024
Q1 		$240K Buy
+900
New +$212K ﹤0.01% 5250
2023
Q4 		– Sell
-115,700
Closed -$16.9M – 7728
2023
Q3 		$16.9M Sell
115,700
-130,500
-53% -$24.6M ﹤0.01% 1822
2023
Q2 		$56.9M Buy
246,200
+9,600
+4% +$2.6M 0.01% 1071
2023
Q1 		$57.3M Buy
236,600
+205,200
+654% +$55.9M 0.01% 1038
2022
Q4 		$9.11M Sell
31,400
-56,700
-64% -$5.55M ﹤0.01% 2346
2022
Q3 		$5.73M Buy
+88,100
New +$6.12M ﹤0.01% 2628

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's MDGL Position: Q2 2026 in Review

JP Morgan Chase reduced its Madrigal Pharmaceuticals (MDGL) stake by 19% in Q2 2026, selling an estimated $3.5M and leaving 29,473 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

JP Morgan Chase first reported a position in MDGL in Q2 2013 and has held it in 42 quarters since. The position peaked at $44M in Q4 2018. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • JP Morgan Chase held 29,473 shares of Madrigal Pharmaceuticals worth $16M as of Q2 2026.
  • JP Morgan Chase sold 6,842 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $3.5M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2400 holding.
  • JP Morgan Chase first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • JP Morgan Chase's Madrigal Pharmaceuticals position peaked at $44M in Q4 2018.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.